





CLAIMS

1. A compound of the formula


where R₁ is of the formulae

III




;


- 5 R_2 is $-R_4$, $-O-R_4$, $-O-S(O)_2-R_4$, $-NR_4R_5$, $R_4-(CH_2)_b-NH(C=X)-(CH_2)_c-$,
 $R_4-(CH_2)_b-O(C=O)NH-(CH_2)_c-(C=O)NH-$, $R_4-(C=O)NH-(C=O)NH-$,
 $-(CH_2)_b-NH(C=X)-(CH_2)_c-R_4$, $R_4-(CH_2)_b-O(C=O)-(CH_2)_c-$, $-(CH_2)_b-O(C=O)-(CH_2)_c-R_4$,
 $-NH(C=X)NH-R_4$, $R_4-O(C=O)O-$, $-O(C=O)NH-R_4$, $R_4-O(C=O)NH-$,
 $-(CH_2)_b-(C=O)-(CH_2)_c-R_4$, $-NH-S(O)_2-R_4$, $-C(OH)R_4R_5$, $-CH(OH)-R_4$, $-(C=O)-NR_4R_5$, $-CN$,
10 $-NO_2$, substituted C_1 to C_6 alkyl, substituted or unsubstituted C_1 to C_6 alkenyl, or
substituted or unsubstituted C_1 to C_6 alkynyl, said substituted moieties substituted with a
moiety of the formulae $-R_4$, $-R_4R_5$, $-O-R_4$, or $-S(O)_d-R_4$;
 R_3 is hydrogen, $CH_3OCH_2CH_2$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, or aryl;
 R_4 and R_5 are each independently



X V



X VI




X VII

- 15 hydrogen, $-CF_3$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, with the proviso that when R_2 is $-R_4$ or $-OR_4$, R_4 is not hydrogen or C_1 to C_6 alkyl;
 R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , and R_{18} are each
independently H, halogen, $-CF_3$, $-(C=O)R_{20}$, $-CN$, $-OR_{20}$, $-NR_{20}R_{21}$, $-NR_{20}SO_2R_{22}$,
 $-N=C-N(CH_3)_2$, $-N_{20}CO_2R_{22}$, $-S(O)_eR_{20}$, $-SO_2NR_{20}R_{21}$, $-NO_2$, aryl, C_1 to C_6 alkylaryl,

- 5 $-(C=O)OR_{20}, -(C=O)NR_{20}R_{21}$, C₁ to C₆ alkyl, C₁ to C₆ alkenyl, and C₁ to C₆ alkynyl;
 R₆ and R₇, R₇ and R₈, R₈ and R₉, R₉ and R₁₀, R₁₁ and R₁₂, R₁₂ and R₁₃, R₁₃ and
 R₁₄, R₁₅ and R₁₆, R₁₆ and R₁₇, and R₁₇ and R₁₈ may be taken together to form a five-to-
 seven-membered alkyl ring, a six-membered aryl ring, a five to seven membered
 heteroalkyl ring having one heteroatom of N, O, or S, or a five-to six-membered
- 10 heteroaryl ring have 1 or 2 heteroatoms of N, O, or S;
 R₁₉ is hydrogen or C₁ to C₃ alkyl;
 R₂₀ and R₂₁ are each independently hydrogen, C₁ to C₆ alkyl, aryl, or C₁ to C₆
 alkylaryl, or may be taken together to form a C₄ to C₇ alkyl ring;
 R₂₂ is C₁ to C₆ alkyl, aryl, or C₁ to C₆ alkylaryl;
- 15 A, B, D, E, and F are each independently C or N;
 G, I, J, and K are each independently C, N, O, S, or (C=O), with the proviso that
 there is at most one of O, (C=O), or S per ring;
 L and Z are each independently C or N;
 M is C, N, or (C₂-24O);
- 20 X is O or S;
 a is 0, 1 or 2;
 e is 0, 1 or 2;
 d is 0, 1, or 2;
 b and c are each independently 0, 1, 2, 3, 4, 5, or 6, with b+c being at most 6;
- 25 a broken line indicates the presence optionally of a double bond and the above
 aryl groups and the aryl moieties of the above alkylaryl groups are independently
 selected from phenyl and substituted phenyl, wherein said substituted phenyl may be
 substituted with one to three groups selected from C₁ to C₄ alkyl, halogen, hydroxy,
 cyano, carboxamido, nitro, and C₁ to C₄ alkoxy, and pharmaceutically acceptable salts
 thereof.
- 30 2. The compound of claim 1, wherein R₁ is formula II; R₂ is -R₄, -OR₄,
 R₄-(CH₂)_b-NH(C=X)-(CH₂)_c-_b, or -(CH₂)_b-NH(C=O)-(CH₂)_c-R₄; R₃ is hydrogen or C₁ to C₆
 alkyl; R₄ is formula XV or formula XVII; A, B, D, E, and F are each independently C or N;
 R₆, R₇, R₈, R₉, R₁₀, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ are each independently hydrogen,
 halogen, -CN, or -OR₂₀; and R₂₀ is C₁ to C₆ alkyl.
- 35 3. The compound of claim 1, wherein R₁ is formula III; R₂ is
 -R₄, -OR₄, R₄-(CH₂)_b-NH(C=X)-(CH₂)_c-_b, or -(CH₂)_b-NH(C=O)-(CH₂)_c-R₄; R₄ is formula XV
 or formula XVII; R₃ is hydrogen or C₁ to C₆ alkyl; A, B, D, E, and F are each
 independently C or N; R₆, R₇, R₈, R₉, R₁₀, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ are each
 independently hydrogen, halogen, -CN, or -OR₂₀; and R₂₀ is C₁ to C₆ alkyl.

5 4. The compound of claim 1, wherein R₁ is

10



R₂ is -R₄, -OR₄, R₄-(CH₂)_b-NH(C=X)-(CH₂)_c-, or -(CH₂)_b-NH(C=O)-(CH₂)_c-R₄; R₃ is hydrogen or C₁ to C₆ alkyl; R₄ is formula XV or formula XVII; A, B, D, E, and F are each independently C or N; R₆, R₇, R₈, R₉, R₁₀, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ are each independently hydrogen, halogen, -CN, or -OR₂₀; and R₂₀ is C₁ to C₆ alkyl.

15

5. The compound of claim 1, wherein R₁ is formula II, formula III, or formula IV; R₂ is -R₄; R₃ is hydrogen or C₁ to C₆ alkyl; R₄ is formula XVII; G, I, J, and K are each independently C, N, or O; L is C; R₁₁, R₁₂, R₁₃, and R₁₄ are each independently hydrogen, C₁ to C₆ alkyl, or C₁ to C₆ alkylaryl.

20 6. The compound of claim 1, said compound being selected from:

7-(Imidazolo[4,5-b]pyridin-1-yl)-1-(1-methylpyrrolidin-3-yl)naphthalene;

7-(4-Chlorobenzamido)-1-(pyrrolidin-2-(R)-ylmethyl)naphthalene;

2-[8-(4-Methylpiperazin-1-yl)naphthalen-2-yloxy]nicotinonitrile;

1-(4-Methylpiperazin-1-yl)-7-pyrimidin-5-yl)naphthalene;

25 7-(5-Cyanopyridin-3-yl)-1-(4-methylpiperazin-1-yl)naphthalene;

1-(Piperazin-1-yl)-7-(pyrimidin-5-yl)naphthalene;

7-(4-Chlorobenzamido-1-(4-methylpiperazin-1-yl)naphthalene;

7-(3-Methoxyphenyl)-1-(4-methylpiperazin-1-yl)naphthalene;

7-(Imidazolo[4,5-b]pyridin-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene;

30 8-(4-Methylpiperazin-1-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide;

7-(4-Methoxyphenyl)-1-(4-methylpiperazin-1-yl)-naphthalene;

7-Pyrimidin-2-yloxy-1-(4-methylpiperazin-1-yl)naphthalene;

7-(Benzimidazol-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene; and

35 8-(1-Methylpiperidin-4-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide.

7. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, Alzheimer's disease, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.


5 8. A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.

10 9. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, Alzheimer's disease, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.


15 10. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.

11. A compound of the formula

20




where R₁ is of the formulae



II

III



- 5 R₂ is (Methyl)₃Sn- or (Butyl)₃Sn-; R₃ is hydrogen , C₁ to C₆ alkyl, C₁ to C₆ alkylaryl, or aryl; a is 0, 1, or 2; and a broken line indicates the presence optionally of a double bond and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl,
- 10 halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₄ alkoxy.